

Examiner's Amendments to the Claims:

Claim 20, 22, 28, 31, 32, 33 and 41 have been amended as follows:

20 (Currently amended). A kit of parts comprising:

(a) a pharmaceutical formulation [including] comprising a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable [derivative] salt or solvate thereof, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier; and

(b) a pharmaceutical formulation [including] comprising a prodrug of the low molecular weight thrombin inhibitor of formulation (a), or a pharmaceutically acceptable [derivative] salt or solvate of that prodrug, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier,

which formulations (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

22 (Currently amended). The kit of parts as claimed in Claim 20, wherein formulations (a) and (b) are suitable for sequential[, separate] or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.

28 (Currently amended). The kit of parts as claimed in Claim 20, 24 or 27, wherein the formulation comprising thrombin inhibitor, or [derivative] salt or solvate thereof, is a parenteral formulation and that comprising the prodrug, or [derivative] salt or solvate thereof, is an oral formulation.

31 (Currently amended). A pharmaceutical formulation [including] comprising:

(i) a low molecular weight thrombin inhibitor [(]or a pharmaceutically acceptable

Art Unit: 1653

[derivative] salt or solvate thereof]); [and]

(ii) a prodrug of the low molecular weight thrombin inhibitor of component (i) [(]or a pharmaceutically acceptable [derivative] salt or solvate of that prodrug[), in admixture with]; and

(iii) a pharmaceutically acceptable [adjuvant,] diluent or carrier.

32 (Currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation [including] comprising a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable [derivative] salt or solvate thereof, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier, [in conjunction] sequentially or simultaneously with

(b) a pharmaceutical formulation [including] comprising a prodrug of the low molecular weight thrombin inhibitor of formulation (a), or a pharmaceutically acceptable [derivative] salt or solvate of that prodrug, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier,

to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

33 (Currently amended). The method as claimed in Claim 32 in which [the] formulation (a) is administered prior to [commencement of] administration of formulation (b).


41 (Currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

Art Unit: 1653

inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation [including] comprising melagatran, or a pharmaceutically acceptable [derivative] salt or solvate thereof, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier, [in conjunction] sequentially or simultaneously with

(b) a pharmaceutical formulation [including] comprising a prodrug of formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab, or a pharmaceutically acceptable [derivative] salt or solvate of that prodrug, in admixture with a pharmaceutically acceptable [adjuvant,] diluent or carrier,

to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.